Contact   |    Careers   |    Employees   |    Physicians

Research


 
 
 

Departments

 
 
 

Research - Research Trials

Open Research Trials at Sibley Memorial Hospital

Please contact Amanda Moser at (202) 660-6420 or by email amoser6@jhmi.edu to learn about the clinical trials offered at Sibley. 

Updated: June 26, 2014
 

Breast Cancer  

E2108
A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer 
 
J0888
Johns Hopkins Breast Cancer Program Longitudinal Repository
 
J1189
Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database
 
J1232 (DIG-HIF1 PK)
Digoxin as a Novel Inhibitor of Global Hypoxia Inducible Factor-1α (HIF-1α) Expression & Downstream Targets in Breast Cancer: DIG-HIF1 Pharmacodynamic Trial
 
J13104 (PBI)
A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with ER Negative Early Stage Breast Cancer
 
ENSABPB43
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
 
NSB47
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer 
 
ES1007
Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial RX for Positive Node, Endocrine Responsive Breast Cancer 
 
J1349
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting 
 
J13165
A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who received no prior therapy for advanced disease
 
E1Z11
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

SIB1392
Combination immunotherapy with Herceptin and the HER2 vaccine E75 in low and intermediate HER2-expressing breast cancer patients to prevent recurrence
 
S1207
Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
 

Gastrointestinal Cancer  

CALGB 80702
A Phase III trials of 6 versus 12 treatment of Adjuvant Treatment of Adjuvant  Folfox plus Celecoxib or Placebo for patient with Resected Stage III Colon Cancer.
 
J1356
STEAM (Sequencing Triplet with Avastin and Maintenance): Folfoxiri/Bevacizumab Regimens (Concurrent and Sequential) Vs. Folfox/Bevacizumab in First-Line Metastatic Colorectal Cancer

 

Genitourinary Cancer  

CALGB90601
A Randomized double-blinded Phase III study comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin,and Placebo in patients with advanced Transitional Cell Carcinoma
 
J11157
Stereotactic Body Radiation Therapy and Short-Term Androgen Ablation for Intermediate-Risk, Localized, Adenocarcinoma of the Prostate
 
J1161 (MPX)
Phase I/II study of safety and efficacy of Muscadine Plus (MPX) in men with prostate cancer: A randomized, double-blind, placebo-controlled study of the effects of two doses of MPX capsule on rising prostate-specific antigen in men following initial ther
 
J12103
A Randomized Gene Fusion Stratified Phase 2 Trial Of Abiraterone With Or Without ABT 888 For Patients With Metastatic Castration-Resistant Prostate Cancer (NCI# 9012)
 
J12125 (Taxynergy)
Phase II Trial to Evaluate Benefit of Early Switch from first-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the opposite sequence, exploring molecular markers and mechanisms of taxane resistance in men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have not received prior chemotherapy
 
J1262 (Biopsy)
Understanding Mechanisms of Response and Resistance to Androgen-Directed Therapies in Men with Advanced Prostate Cancer Through Interrogation of Tumor Biopsies: A Pilot/Feasibility Study
 
J1328 (ARMOR2)
A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer
 
J1391 (XL-184-307)
A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy
 
R0926
A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging
 
S1216
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy TAK-700 With Androgen Deprivation Therapy Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
 
J1315 (ARN-509-003)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer

J1332 (LCCC-1231)
Observational Longitudinal Study of Pain in Men with Metastatic Castrate-Resistant Prostate Cancer
 
J1307 (ABICURE)
Abiraterone alone, abiraterone plus degarelix, a GnRH antagonist, and degarelix alone for prostate ca w/ rising PSA or a rising PSA and nodal disease following definitive radical prostatectomy
 
J1336
Race as a Risk Factor for Metastatic Prostate Cancer: A Sentinel Event Case Series
 
J1416 (RESTORE)
A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) followed by Enzalutamide or Abiraterone Post-BAT in Men with Prostate Cancer Progressing on Combined Androgen Ablative Therapies
 

Gynecologic Cancer  

GOG 0258
A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
 
GOG 0263
A Randomized Phase III Clinical  Trial of  Adjuvant Radiation Versus Chemoradiation  In Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy. 
 
G0238
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin In Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
 
G0277
A Phase III Randomized Trial of Gemcitabine plus Docetaxel Followed by Doxorubicin versus Observation for Uterus-Limited High-Grade Uterine Leiomyosarcoma

 

Kidney Cancer

There are no open studies at this time.

 

Lung Cancer  

ECOG 5508
Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC 

SIB1301
Amgen: Evaluate the Long-Term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects w/ Advanced Stage NSCLC Receiving Multi-Cycle Chemo
 
 

Leukemia/Lymphoma  

There are no open studies at this time.

 

Melanoma  

ECOG 1609
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α- 2b for Resected High-Risk Melanoma 
 
© Copyright 2013 Sibley Memorial Hospital